Cytokinetics (CYTK) PT Raised to $75 at H.C. Wainwright, "Aficamten Is Next and Could Do Better" than BMY's Recently Approved Camzyos
Tweet Send to a Friend
H.C. Wainwright analyst Joseph Pantginis raised the price target on Cytokinetics (NASDAQ: CYTK) to $75.00 (from $69.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
